NCT04665830View on ClinicalTrials.gov

PCSK 9 Inhibition as Secondary Prevention in Renal Transplant Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

May 1, 2018

Primary Completion Date

May 1, 2020

Study Completion Date

May 1, 2020

Conditions
Kideny Transplant Recipients With High Cardiovascular Risk Score
Interventions
DRUG

Evolocumab

treated patients with evolocumab for high cholesterol

Trial Locations (1)

Kuwait

OTC, MOH , Kuwait, Kuwait City

All Listed Sponsors
lead

Hamid Al-Essa Organ Transplant Center

OTHER_GOV

NCT04665830 - PCSK 9 Inhibition as Secondary Prevention in Renal Transplant Patients | Biotech Hunter | Biotech Hunter